[go: up one dir, main page]

DE60313444D1 - Vegf-peptide und deren verwendung - Google Patents

Vegf-peptide und deren verwendung

Info

Publication number
DE60313444D1
DE60313444D1 DE60313444T DE60313444T DE60313444D1 DE 60313444 D1 DE60313444 D1 DE 60313444D1 DE 60313444 T DE60313444 T DE 60313444T DE 60313444 T DE60313444 T DE 60313444T DE 60313444 D1 DE60313444 D1 DE 60313444D1
Authority
DE
Germany
Prior art keywords
vegf
peptides
sckntdsrckarqlelnertcrcdkprr
fragment
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60313444T
Other languages
English (en)
Other versions
DE60313444T2 (de
Inventor
D Selwood
M Loehr
I Zachary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ark Therapeutics Ltd
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Application granted granted Critical
Publication of DE60313444D1 publication Critical patent/DE60313444D1/de
Publication of DE60313444T2 publication Critical patent/DE60313444T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60313444T 2002-04-02 2003-03-28 Vegf-peptide und deren verwendung Expired - Fee Related DE60313444T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0207644.6A GB0207644D0 (en) 2002-04-02 2002-04-02 Peptides and their use
GB0207644 2002-04-02
PCT/GB2003/001375 WO2003082918A1 (en) 2002-04-02 2003-03-28 Vegf peptides and their use

Publications (2)

Publication Number Publication Date
DE60313444D1 true DE60313444D1 (de) 2007-06-06
DE60313444T2 DE60313444T2 (de) 2007-08-30

Family

ID=9934136

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313444T Expired - Fee Related DE60313444T2 (de) 2002-04-02 2003-03-28 Vegf-peptide und deren verwendung

Country Status (17)

Country Link
US (1) US20060166868A1 (de)
EP (1) EP1490401B1 (de)
JP (1) JP2005531527A (de)
KR (1) KR100641535B1 (de)
CN (1) CN1642979A (de)
AT (1) ATE360644T1 (de)
AU (1) AU2003226515B2 (de)
CA (1) CA2481253A1 (de)
DE (1) DE60313444T2 (de)
ES (1) ES2283799T3 (de)
GB (1) GB0207644D0 (de)
IL (1) IL163799A0 (de)
MX (1) MXPA04009479A (de)
NO (1) NO20044105L (de)
PL (1) PL371546A1 (de)
WO (1) WO2003082918A1 (de)
ZA (1) ZA200406922B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US7148199B2 (en) 2003-09-26 2006-12-12 University Of Florida Research Foundation, Inc. Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation
CN1904150B (zh) * 2006-08-01 2010-07-28 华东师范大学 一种人胰高血糖素样肽-1衍生物及其固相化学合成
GB0619609D0 (en) * 2006-10-04 2006-11-15 Ark Therapeutics Ltd Compounds and their use
GB0619611D0 (en) * 2006-10-04 2006-11-15 Ark Therapeutics Ltd Compounds and their use
CN104774246B (zh) * 2014-03-21 2018-05-04 中山大学附属肿瘤医院 Nrp-1特异性肿瘤靶向多肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008473A1 (en) * 1991-10-24 1993-04-29 Beth Israel Hospital Association Assay for malignant effusions
AU1810899A (en) * 1997-12-09 1999-06-28 Children's Medical Center Corporation Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
US7045133B2 (en) * 2000-01-18 2006-05-16 Ludwig Institute For Cancer Research VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor

Also Published As

Publication number Publication date
WO2003082918A1 (en) 2003-10-09
AU2003226515A1 (en) 2003-10-13
DE60313444T2 (de) 2007-08-30
AU2003226515B2 (en) 2006-06-08
ES2283799T3 (es) 2007-11-01
IL163799A0 (en) 2005-12-18
EP1490401B1 (de) 2007-04-25
ZA200406922B (en) 2006-06-28
KR20040099356A (ko) 2004-11-26
CA2481253A1 (en) 2003-10-09
EP1490401A1 (de) 2004-12-29
KR100641535B1 (ko) 2006-10-31
PL371546A1 (en) 2005-06-27
CN1642979A (zh) 2005-07-20
JP2005531527A (ja) 2005-10-20
US20060166868A1 (en) 2006-07-27
MXPA04009479A (es) 2005-01-25
GB0207644D0 (en) 2002-05-15
NO20044105L (no) 2004-10-27
ATE360644T1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
CY1117551T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
NO2017027I2 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
AU2003250402A8 (en) Beta-sheet forming peptides and material made thereof
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
EP1587834A4 (de) Verwendungen von säuger-cytokin; verwandte reagenzien
DE60010098D1 (de) 28-epirapaloge
CY1108547T1 (el) Αναλογα σωματοστατινης
EA200500019A1 (ru) Ксиланазы, кодирующие их нуклеиновые кислоты и способы их получения и применения
DE50204766D1 (de) Verwendung von kreatin, kreatinin und/oder cyclokreatin zur stärkung und verbesserung der haarstruktur
BR0313792A (pt) Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
NO20044398L (no) Fotokatalysatorer inneholdende titanoksyd, samt fremgangsmate og anvendelse derav
DE60313444D1 (de) Vegf-peptide und deren verwendung
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
DE60327084D1 (de) Verwendung von n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3-sulphonamid in der tumortherapie
PL1603584T3 (pl) Aplidyna do leczenia szpiczaka mnogiego
ATE533779T1 (de) Isoliertes photoprotein mtclytin, sowie dessen verwendung
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
ATE548037T1 (de) Peptid-deformylase-hemmer
DE60207833D1 (de) Peptiddeformylase-hemmer
DE60334533D1 (de) Gewebe-engineering
ATE528392T1 (de) Neues protein und dessen dns
EP1566386A4 (de) Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür
ATE514683T1 (de) Peptid-deformylase-hemmer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee